Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG

被引：0

作者：

Sudbrock, F.

Eschner, W.

Schmidt, M.

Simon, T.

Hero, B.

Schicha, H.

机构：

[1] Univ Cologne, Nukl Med Klin & Poliklin, D-50937 Cologne, Germany

[2] Univ Cologne, Zentrum Kinderonkol & Hamatol, D-50937 Cologne, Germany

来源：

NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2006年 / 45卷 / 06期

关键词：

neuroblastom; mIBG-Therapie; ganzkorperszintigraphie; SPECT dosimetrie; energiedosis;

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Aim: Targeted radiotherapies using iodine-131 meta-iodobenzylguanidin have long been in use for treatment of stage IV neuroblastoma but reliable dosimetric data are scarce. Method: This work presents an approach to determine the whole body exposure and tumour doses delivered during therapy. Dosimetric data are reported and discussed for six treatments carried out according to the trial protocol NB2004 as it is in use in our study in the last two years. Results: Whole body exposures are found to be in the range of 1.75 to 2.5 Gy whereas tumour doses vary between 15 and 55 Gy. Conclusion: The course of action prescribed by the trial protocol allows whole body exposure as well as tumour doses to be determined routinely.

引用

页码：254 / 261

页数：8

共 50 条

[41] THE ROLE OF 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) THERAPY IN UNRESECTABLE AND COMPROMISING LOCALIZED NEUROBLASTOMA
Schoot, Reineke
Bleeker, Gitta
Heij, Hugo
van Eck, Berthe
Caron, Huib
de Kraker, Jan
PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 807 - 808
[42] Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans
Myriam Monsieurs
Boudewijn Brans
Klaus Bacher
Rudi Dierckx
Hubert Thierens
European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29 : 1581 - 1587
[43] 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma: An individualised approach
George, S.
Kirk, S. J.
Lancaster, D.
Vaidya, S. J.
Mandeville, H.
Saran, F.
Chittenden, S.
Pearson, A. D. J.
Du, Y.
Flux, G. D.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S352 - S352
[44] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results
Buckley, S.
Flux, G.
Gaze, M.
Chittenden, S.
Partridge, M.
Lancaster, D.
Pearson, A.
Saran, F.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S339 - S339
[45] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma:: Preliminary results
Buckley, Susan E.
Saran, Frank H.
Gaze, Mark N.
Chittenden, Sarah
Partridge, Mike
Lancaster, Donna
Pearson, Andrew
Flux, Glenn D.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (01) : 105 - 112
[46] Tumor Dosimetry And Radiobiological Study For High-Activity 131I-mIBG Therapy In The Management Of Refractory/Relapsed Neuroblastoma
Polito, C.
Cassano, B.
Genovese, E.
Longo, M.
Donatiello, S.
Insero, T.
Valeri, S.
Villani, M. F.
Castellano, A.
Garganese, M. C.
Cannata, V.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S484 - S484
[47] Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans
Monsieurs, M
Brans, B
Bacher, K
Dierckx, R
Thierens, H
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (12) : 1581 - 1587
[48] 131I-MIBG therapy with WT-1 peptide for refractory neuroblastoma
Sugiyama, Minako
Seigo, Kinuya
Hosoya, Yosuke
Iguchi, Akihiro
Manabe, Atsushi
PEDIATRICS INTERNATIONAL, 2020, 62 (06) : 746 - 747
[49] Evaluation of ctDNA in children with relapsed or refractory neuroblastoma treated with 131I-MIBG
Shulman, David S.
Klega, Kelly
Marachelian, Araz
Matthay, Katherine K.
Park, Julie R.
Granger, M. Meaghan
DuBois, Steven G.
Crompton, Brian D.
CLINICAL CANCER RESEARCH, 2020, 26 (11) : 66 - 66
[50] Radiotoxicity after 131I-MIBG therapy for neuroblastoma and carcinoid tumors.
Monsieurs, MA
Thierens, H
Vral, A
Brans, B
De Ridder, L
Dierckx, RA
JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 272P - 273P

← 1 2 3 4 5 →